Xlinktx
Crosslink Therapeutics is developing a modular biologic platform that leverages elevated extracellular ATP levels in solid tumors to conditionally assemble therapeutic agents directly within the tumor microenvironment. The company is currently advancing applications in antibody-drug conjugates and radioligand therapies, aiming to improve tumor-specific targeting and reduce off-tumor effects.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
Funding
Founders
Founder details are not available yet.
Product
Problem
Extracellular adenosine triphosphate (eATP) is released at high levels by solid tumors, creating a biochemical environment that differs markedly from normal tissue. This tumor-specific elevation of eATP supports cancer development and growth, yet standard therapeutic approaches do not exploit this difference, often leading to off-target effects and limited efficacy in treating solid tumors.
Solution
Crosslink has engineered a modular biologic domain that takes advantage of the elevated eATP concentrations in solid tumors to drive the assembly of therapeutic agents directly within the tumor microenvironment. This domain can be attached to virtually any therapeutic modality, enabling tumor-specific targeting and enhanced activity while minimizing effects on healthy tissue. The company is currently advancing first-in-class and best-in-class applications in antibody-drug conjugates and radioligand therapies, using this eATP-dependent assembly mechanism to concentrate treatment where it is needed most.
Target Audience
Crosslink's primary customers and partners are pharmaceutical and biotechnology companies developing targeted cancer therapeutics, particularly those focused on antibody-drug conjugates and radioligand therapies for solid tumors.
Features
- Modular biologic domain responsive to elevated extracellular ATP levels in solid tumors
- Platform compatible with a broad range of therapeutic modalities, including antibody-drug conjugates and radioligand therapies
- Tumor-specific assembly mechanism designed to improve tissue targeting and reduce off-tumor activity
- Applicable to both first-in-class and best-in-class therapeutic development programs